AbbVie Inc. (NYSE:ABBV) is AEGON ASSET MANAGEMENT UK Plc's 10th Largest Position

AEGON ASSET MANAGEMENT UK Plc grew its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 17.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 585,766 shares of the company's stock after purchasing an additional 87,891 shares during the period. AbbVie comprises about 1.8% of AEGON ASSET MANAGEMENT UK Plc's portfolio, making the stock its 10th biggest position. AEGON ASSET MANAGEMENT UK Plc's holdings in AbbVie were worth $122,371,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. CGN Advisors LLC boosted its holdings in AbbVie by 10.3% in the 1st quarter. CGN Advisors LLC now owns 2,045 shares of the company's stock worth $428,000 after acquiring an additional 191 shares during the period. Kwmg LLC increased its holdings in shares of AbbVie by 10.3% during the first quarter. Kwmg LLC now owns 1,372 shares of the company's stock valued at $287,000 after purchasing an additional 128 shares during the period. RFG Advisory LLC boosted its stake in AbbVie by 43.4% during the first quarter. RFG Advisory LLC now owns 38,444 shares of the company's stock valued at $8,055,000 after buying an additional 11,628 shares in the last quarter. Capital Asset Advisory Services LLC boosted its position in shares of AbbVie by 7.5% in the 1st quarter. Capital Asset Advisory Services LLC now owns 19,828 shares of the company's stock valued at $4,068,000 after purchasing an additional 1,380 shares during the period. Finally, Merit Financial Group LLC boosted its position in AbbVie by 19.9% during the 1st quarter. Merit Financial Group LLC now owns 59,033 shares of the company's stock worth $12,369,000 after acquiring an additional 9,807 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on ABBV shares. Evercore ISI lifted their price target on AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. Erste Group Bank raised shares of AbbVie to a "strong-buy" rating in a report on Monday, March 17th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $194.00 price target on shares of AbbVie in a research report on Tuesday, April 8th. BNP Paribas upgraded shares of AbbVie to a "hold" rating in a report on Thursday, May 8th. Finally, Citigroup reiterated a "neutral" rating and issued a $205.00 price objective (down previously from $210.00) on shares of AbbVie in a research note on Wednesday, May 14th. Eight investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $210.95.

Insider Buying and Selling at AbbVie

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the business's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the sale, the executive vice president now directly owns 53,234 shares in the company, valued at approximately $11,183,398.72. The trade was a 52.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.25% of the company's stock.

AbbVie Stock Performance

ABBV stock traded down $0.05 during trading hours on Thursday, hitting $187.29. 4,289,978 shares of the stock were exchanged, compared to its average volume of 6,233,048. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The firm has a market capitalization of $330.82 billion, a P/E ratio of 78.04, a P/E/G ratio of 1.62 and a beta of 0.56. The company has a 50-day simple moving average of $185.01 and a two-hundred day simple moving average of $186.65. AbbVie Inc. has a 12 month low of $162.16 and a 12 month high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.40 by $0.06. The firm had revenue of $13.34 billion for the quarter, compared to analysts' expectations of $12.91 billion. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The company's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the business earned $2.31 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.